hotspot -WSS

hotspot

author：leisure time 2025-10-03 00:38:37 - browse：89373

US Capitol - SOTU — Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： In key trial, Verve's treatment lowers cholesterol levels in patients

WSS

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Disappointing trial forces Pfizer to pivot on obesity medicine plans

NYU radiologists take on the challenge of expensive MRI machines

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Despite FDA concern, risk that CAR

Congress must reauthorize a committee to support older Americans

focus

hotspot

leisure time

Virginia high school admissions case could be legal follow

What to do when lifesaving products contribute to climate change

Sports medicine is finally prioritizing gender equality

Takeda, Janssen join wearable maker to measure scratching

Psychedelics group wrestles with new pharma identity

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Sports medicine is finally prioritizing gender equality

FDA's Woodcock to retire early next year

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Anthos stroke drug appears safer than common blood thinner

entertainment

Morphosys mixed study results for blood cancer drug

Fetal surgery at risk from Dobbs and new abortion restrictions

CDC director unscathed in first congressional testimony

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

CRISPR pioneers react to Casgevy, first gene

Astellas still sees hope in its gene therapy after four deaths

hotspot

focus

leisure time

focus